Tandem Diabetes Care Inc. (TNDM) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Tandem Diabetes Care Inc. (TNDM) advanced +0.56% to $19.79, trading at 43% of its 52-week range ($12.26 – $29.65). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
SAN DIEGO, October 30, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor
Rapid Micro Biosystems (RPID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and finan
Tandem Diabetes Care shares have climbed back from a deep multi year slump, which puts a fresh spotlight on what investors are paying for each dollar of the company’s sales today. With the stock changing hands at about U
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +7.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TNDM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TNDM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Tandem Diabetes Care Inc. (TNDM) ranks #814 by composite RQD confidence (35/100, grade D-) and #314 by equity capitalization ($1.38B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with TNDM at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TNDM
ACTIVE
Tandem Diabetes Care Inc. | D- | 35/100 | — | 53.8% | -35.0% | +0.56% | $1.38B | Benchmark Subject |
| BVS Bioventus Inc. (Class A) | C+ | 66/100 | 55.0x | 68.3% | 10.4% | +1.50% | $1.25B | /bvs-vs-tndm → |
| NVCR NovoCure Limited | E | 24/100 | — | 74.5% | -27.5% | -7.48% | $1.53B | /nvcr-vs-tndm → |
| DRTS Alpha Tau Medical Ltd. | E | 33/100 | — | — | -35.0% | -0.90% | $1.22B | /drts-vs-tndm → |
| PRCT PROCEPT BioRobotics Corporation | D | 48/100 | — | 63.7% | -35.0% | +0.50% | $1.16B | /prct-vs-tndm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tandem Diabetes Care Inc. (TNDM) reported GAAP revenue of $1.01B (+7.9% vs. FY2024 revenue of $940.2M , and +35.7% cumulative change since FY2023) , GAAP net income of -$204.7M, operating cash flow of -$9.7M, and free cash flow of -$29.7M (-694.1% YoY). On the balance sheet, TNDM closed FY2025 with $881.1M in total assets against $310.0M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.01B | -$204.7M | -$9.7M | -$29.7M | $881.1M | $310.0M |
| FY2024 (FY) | 2024-12-31 | $940.2M | -$96.0M | $24.2M | $5.0M | $967.7M | $308.3M |
| FY2023 (FY) | 2023-12-31 | $747.7M | -$222.6M | -$31.8M | -$31.8M | — | — |
As of 2026-11-01, Tandem Diabetes Care Inc. (NASDAQ: TNDM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $19.79 (+0.56% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TNDM ranks #814 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), TNDM carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 53.8%, and ROIC of -35.0%. By comparison, BVS (Bioventus Inc. (Class A)) holds a C+ grade (66/100 RQD, P/E 55.0x, ROIC 10.4%, cap $1.25B) and NVCR (NovoCure Limited) posts a E grade (24/100 RQD, P/E N/A, ROIC -27.5%, cap $1.53B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).
Per TNDM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001438133), Tandem Diabetes Care Inc. generated $1.01B in revenue (+7.9% YoY), -$204.7M in net income, and -$29.7M in free cash flow against $881.1M in total assets and $310.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
TNDM last traded at $19.79 (+0.56% on volume of 3,357,378 shares), positioning the stock +9.82% above its 50-day simple moving average ($18.02) and +4.54% above its 200-day simple moving average ($18.93). Across its 52-week range of $12.26 to $29.65, TNDM sits at the 43.3% percentile with a 14-day RSI of 62.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.8% ($17.45 to $22.13).
Why TNDM Stock advanced +0.56% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.